ID: ALA2385905

Max Phase: Preclinical

Molecular Formula: C28H25ClN2O3

Molecular Weight: 472.97

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCc1ccc(-c2ccc(C(=O)N3CCc4c(c5cccc(Cl)c5n4CC(=O)O)C3)cc2)cc1

Standard InChI:  InChI=1S/C28H25ClN2O3/c1-2-18-6-8-19(9-7-18)20-10-12-21(13-11-20)28(34)30-15-14-25-23(16-30)22-4-3-5-24(29)27(22)31(25)17-26(32)33/h3-13H,2,14-17H2,1H3,(H,32,33)

Standard InChI Key:  UFMGJYNRGIGTIF-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 472.97

Molecular Weight (Monoisotopic): 472.1554

AlogP: 5.81

#Rotatable Bonds: 5

Polar Surface Area: 62.54

Molecular Species: ACID

HBA: 3

HBD: 1

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.82

CX Basic pKa:

CX LogP: 5.74

CX LogD: 2.48

Aromatic Rings: 4

Heavy Atoms: 34

QED Weighted: 0.40

Np Likeness Score: -1.08

References

1. Fretz H, Valdenaire A, Pothier J, Hilpert K, Gnerre C, Peter O, Leroy X, Riederer MA..  (2013)  Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.,  56  (12): [PMID:23721423] [10.1021/jm400122f]

Source

Source(1):

• Scientific Literature